Arizona 2024 Regular Session

Arizona Senate Bill SB1165 Compare Versions

OldNewDifferences
1-Senate Engrossed pharmacy audit; procedures; prohibition State of Arizona Senate Fifty-sixth Legislature Second Regular Session 2024 CHAPTER 51 SENATE BILL 1165 An Act amending section 20-3322, Arizona Revised Statutes; relating to pharmacy benefits. (TEXT OF BILL BEGINS ON NEXT PAGE)
1+Senate Engrossed pharmacy audit; procedures; prohibition State of Arizona Senate Fifty-sixth Legislature Second Regular Session 2024 SENATE BILL 1165 An Act amending section 20-3322, Arizona Revised Statutes; relating to pharmacy benefits. (TEXT OF BILL BEGINS ON NEXT PAGE)
2+
3+
24
35
46
57
68
79 Senate Engrossed pharmacy audit; procedures; prohibition
810 State of Arizona Senate Fifty-sixth Legislature Second Regular Session 2024
9-CHAPTER 51
1011 SENATE BILL 1165
1112
1213 Senate Engrossed
1314
1415
1516
1617 pharmacy audit; procedures; prohibition
18+
19+
1720
1821
1922
2023
2124
2225
2326
2427 State of Arizona
2528
2629 Senate
2730
2831 Fifty-sixth Legislature
2932
3033 Second Regular Session
3134
3235 2024
3336
3437
3538
3639
3740
3841
3942
40-CHAPTER 51
43+SENATE BILL 1165
4144
4245
43-
44-SENATE BILL 1165
4546
4647
4748
4849
4950
5051
5152
5253 An Act
5354
5455
5556
5657 amending section 20-3322, Arizona Revised Statutes; relating to pharmacy benefits.
5758
5859
5960
6061
6162
6263 (TEXT OF BILL BEGINS ON NEXT PAGE)
6364
6465
6566
6667 Be it enacted by the Legislature of the State of Arizona: Section 1. Section 20-3322, Arizona Revised Statutes, is amended to read: START_STATUTE20-3322. Audit procedures; interest prohibition; claim payment reduction A. The following procedures apply to an audit conducted by an auditing entity: 1. When conducting an in-pharmacy audit an auditing entity shall: (a) Give a pharmacy at least fourteen days' written notice. (b) Not conduct an audit during the first five days of the month unless the pharmacy otherwise consents. (c) Provide the pharmacy a list of items to be audited that provides for identification of prescription number or numbers or date range that the auditing entity is seeking to audit. (d) When conducting an in-pharmacy audit or desktop audit, limit the audit to claims that may do not exceed two years from the date that the claim was adjudicated by the pharmacy benefits manager. 2. An in-pharmacy audit or desktop audit that involves clinical or professional judgment shall be conducted by or in consultation with a pharmacist. 3. The pharmacy may use the records of a hospital, physician or other authorized practitioner to validate the pharmacy records. The validated records may be obtained via electronic methods, fax, phone telephone or written prescription orders and do not have to be the original hard copy prescription order. 4. Each pharmacy shall be audited under the same standards and parameters as other similarly situated pharmacies in this state. 5. When conducting a wholesale invoice audit, an auditing entity shall: (a) not audit the pharmacy claims of another auditing entity. (b) Reverse a finding of discrepancy if the pharmacist or pharmacy dispensed the correct quantity of the drug according to the prescription and either of the following applies: (i) The national drug code published by the United States food and drug administration is in a quantity that is a subunit or multiple of the drug purchased by the pharmacist or pharmacy according to the supplier invoice. (ii) The drug dispensed by the pharmacist or pharmacy shares all but the last two digits of the United states food and drug administration's national drug code of the drug reflected on the supplier invoice. (c) As a presumption of validity of a purchase of a dispensed drug, Accept any of the following to support the pharmacy's claim related to a dispensed drug: (i) Copies of the supplier invoices in the pharmacist's or pharmacy's possession, subject to validation that includes validating the pharmacy purchase order and the PAYMENT of the supplier invoice, and including Any SUPPLIER invoices that were issued before the date the drug was dispensed but not earlier than ninety days before the first day of the audit period and Any other invoices and supporting documentation from a supplier that is authorized by federal or state law to transfer ownership of the drug to the pharmacist or pharmacy. The validation may also require information that is required under the drug supply chain security act (P.L. 113-54; 127 Stat. 599; 21 United States Code sections 360eee through 360eee-4). (ii) Any Reports required by a state board or agency. (d) Not later than the tenth business day after receiving the pharmacy's request, provide any supporting documentation that the pharmacy supplier provided to the AUDITING entity. B. When conducting an in-pharmacy audit or desktop audit, an auditing entity shall comply with the following requirements: 1. The auditing entity shall base a finding of overpayment or underpayment on the actual overpayment or underpayment and not on a projection based on the number of patients served who have similar diagnoses or on the number of similar orders or refills for similar drugs, unless required by federal or state law. 2. The auditing entity may not recoup monies from the pharmacy for any clerical errors identified in an audit. 3. Any finding of an overpayment may not include the dispensing fee amount unless any of the following criteria are is met: (a) A prescription was not received by the patient or the patient's designee. (b) The prescriber denied authorization. (c) The prescription dispensed was a medication error by the pharmacy. (d) The identified overpayment is based solely on an extra dispensing fee. C. Interest may not accrue during the audit period. D. An auditing entity may not, directly or indirectly, retroactively reduce the amount of a claim payment to a pharmacist or a pharmacy after adjudication of the claim for a prescription drug unless any of the following applies: 1. The original claim was found to have been fraudulently submitted through an audit conducted in accordance with this article. 2. The claim submitted was a duplicate for which the pharmacy had already received payment. 3. The original reimbursement was incorrect due to an error that resulted in an overpayment by an insurer or a pharmacy benefit manager. E. Subsection D of this section does not prohibit an auditing entity, insurer or pharmacy benefit manager from increasing the amount of a claim payment after adjudication of the claim. END_STATUTE
6768
6869 Be it enacted by the Legislature of the State of Arizona:
6970
7071 Section 1. Section 20-3322, Arizona Revised Statutes, is amended to read:
7172
7273 START_STATUTE20-3322. Audit procedures; interest prohibition; claim payment reduction
7374
7475 A. The following procedures apply to an audit conducted by an auditing entity:
7576
7677 1. When conducting an in-pharmacy audit an auditing entity shall:
7778
7879 (a) Give a pharmacy at least fourteen days' written notice.
7980
8081 (b) Not conduct an audit during the first five days of the month unless the pharmacy otherwise consents.
8182
8283 (c) Provide the pharmacy a list of items to be audited that provides for identification of prescription number or numbers or date range that the auditing entity is seeking to audit.
8384
8485 (d) When conducting an in-pharmacy audit or desktop audit, limit the audit to claims that may do not exceed two years from the date that the claim was adjudicated by the pharmacy benefits manager.
8586
8687 2. An in-pharmacy audit or desktop audit that involves clinical or professional judgment shall be conducted by or in consultation with a pharmacist.
8788
8889 3. The pharmacy may use the records of a hospital, physician or other authorized practitioner to validate the pharmacy records. The validated records may be obtained via electronic methods, fax, phone telephone or written prescription orders and do not have to be the original hard copy prescription order.
8990
9091 4. Each pharmacy shall be audited under the same standards and parameters as other similarly situated pharmacies in this state.
9192
9293 5. When conducting a wholesale invoice audit, an auditing entity shall:
9394
9495 (a) not audit the pharmacy claims of another auditing entity.
9596
9697 (b) Reverse a finding of discrepancy if the pharmacist or pharmacy dispensed the correct quantity of the drug according to the prescription and either of the following applies:
9798
9899 (i) The national drug code published by the United States food and drug administration is in a quantity that is a subunit or multiple of the drug purchased by the pharmacist or pharmacy according to the supplier invoice.
99100
100101 (ii) The drug dispensed by the pharmacist or pharmacy shares all but the last two digits of the United states food and drug administration's national drug code of the drug reflected on the supplier invoice.
101102
102103 (c) As a presumption of validity of a purchase of a dispensed drug, Accept any of the following to support the pharmacy's claim related to a dispensed drug:
103104
104105 (i) Copies of the supplier invoices in the pharmacist's or pharmacy's possession, subject to validation that includes validating the pharmacy purchase order and the PAYMENT of the supplier invoice, and including Any SUPPLIER invoices that were issued before the date the drug was dispensed but not earlier than ninety days before the first day of the audit period and Any other invoices and supporting documentation from a supplier that is authorized by federal or state law to transfer ownership of the drug to the pharmacist or pharmacy. The validation may also require information that is required under the drug supply chain security act (P.L. 113-54; 127 Stat. 599; 21 United States Code sections 360eee through 360eee-4).
105106
106107 (ii) Any Reports required by a state board or agency.
107108
108109 (d) Not later than the tenth business day after receiving the pharmacy's request, provide any supporting documentation that the pharmacy supplier provided to the AUDITING entity.
109110
110111 B. When conducting an in-pharmacy audit or desktop audit, an auditing entity shall comply with the following requirements:
111112
112113 1. The auditing entity shall base a finding of overpayment or underpayment on the actual overpayment or underpayment and not on a projection based on the number of patients served who have similar diagnoses or on the number of similar orders or refills for similar drugs, unless required by federal or state law.
113114
114115 2. The auditing entity may not recoup monies from the pharmacy for any clerical errors identified in an audit.
115116
116117 3. Any finding of an overpayment may not include the dispensing fee amount unless any of the following criteria are is met:
117118
118119 (a) A prescription was not received by the patient or the patient's designee.
119120
120121 (b) The prescriber denied authorization.
121122
122123 (c) The prescription dispensed was a medication error by the pharmacy.
123124
124125 (d) The identified overpayment is based solely on an extra dispensing fee.
125126
126127 C. Interest may not accrue during the audit period.
127128
128129 D. An auditing entity may not, directly or indirectly, retroactively reduce the amount of a claim payment to a pharmacist or a pharmacy after adjudication of the claim for a prescription drug unless any of the following applies:
129130
130131 1. The original claim was found to have been fraudulently submitted through an audit conducted in accordance with this article.
131132
132133 2. The claim submitted was a duplicate for which the pharmacy had already received payment.
133134
134135 3. The original reimbursement was incorrect due to an error that resulted in an overpayment by an insurer or a pharmacy benefit manager.
135136
136137 E. Subsection D of this section does not prohibit an auditing entity, insurer or pharmacy benefit manager from increasing the amount of a claim payment after adjudication of the claim. END_STATUTE
137-
138- APPROVED BY THE GOVERNOR MARCH 29, 2024. FILED IN THE OFFICE OF THE SECRETARY OF STATE MARCH 29, 2024.
139-
140-
141-
142-
143-
144-
145-
146-APPROVED BY THE GOVERNOR MARCH 29, 2024.
147-
148-
149-
150-FILED IN THE OFFICE OF THE SECRETARY OF STATE MARCH 29, 2024.